Budd-Chiari Syndrome: An Unusual Complication of Sarcoidosis

Raja Amri¹, Rabie Ayari², Mouna Medhioub³, Manel Loukil⁴, Haifa Tounsi¹ and Mohamed Ali Sbai²*

¹Internal Medicine Department, Maamouri Hospital, Nabeul, Tunisia Medical University of Tunis Manar, Tunisia.
²Plastic, Hand Surgery and Burns Department, Maamouri Hospital, Nabeul, Tunisia, Medical university of Tunis Manar, Tunisia.
³Gastroenterology Department, Maamouri Hospital, Nabeul, Tunisia Medical University of Tunis Manar, Tunisia.
⁴Pulmonology Department, Maamouri Hospital, Nabeul, Tunisia and Medical University of Tunis Manar, Tunisia.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors Raja Amri and Rabie Ayari designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors MM and ML managed the analyses of the study. Authors HT and MAS managed the literature searches. All authors read and approved the final manuscript.

Article Information

Editor(s):
(1) Dr. Wagih Mommtaz Ghannam, Mansoura University, Egypt.
Reviewers:
(1) Vaibhav Anjankar, Datta Meghe Institute of Medical Sciences, Jawaharlal Nehru medical College, India.
(2) D. B. Mondal, Indian Council of Agricultural Research (ICAR), India.
Complete Peer review History: http://www.sdiarticle4.com/review-history/59447

Received 23 May 2020
Accepted 28 July 2020
Published 01 September 2020

ABSTRACT

Hepatic involvement during sarcoidosis is common but rarely symptomatic. Budd-Chiari syndrome is an exceptional but potentially serious complication.

A case of 38-year-old woman was diagnosed with a Budd-Chiari syndrome complicating multisystemic sarcoidosis has been reported in present case study. The patient was treated with hydroxychloroquine and long-term corticosteroid therapy with favorable clinical and radiologic outcomes.

Although BCS is an exceptional complication of hepatic sarcoidosis, it should always considered. A Doppler ultrasound should be performed in front of any evocating sign to establish an early diagnosis.

*Corresponding author: E-mail: mohamedali.sbai@ms.tn;
Keywords: Sarcoidosis; Budd-Chiari syndrome; cholestasis.

1. INTRODUCTION

Sarcoidosis is an inflammatory disease with poorly known etiologies. It is often caused by an exaggerated immune response to some antigens of susceptible individuals [1].

It is a systemic granulomatosis. The main localization are lymph node and lungs, but it can involve several other organs [2-4]. Extra pulmonary manifestations are reported in half of the cases of systemic sarcoidosis [5]. Liver involvement is often asymptomatic. Clinical involvement is observed in less than 20% of cases. In symptomatic patients, elevated liver enzymes are present in only 10-30% of cases [5,6] and hepatosplenomegaly is noted in about 20% of cases [2].

Bud Chiari syndrome (BCS) is exceptional during sarcoidosis [7].

2. CASE PRESENTATION

In present report, a case of a Tunisian 38-year-old patient with a 4-year history of type 2 diabetes and 8-year history of multisystemic sarcoidosis with skin, lymph node and lung involvement, was reported. The diagnosis was established in front of several findings: disseminated erythematous squamous papular plaques (Fig. 1), hypercalcemia, elevation of angiotensin II converting enzyme, hilar and mediastinal adenopathies with pulmonary parenchymal involvement associated with cutaneous and bronchial granulomatosis.

The patient was treated with hydroxychloroquine and long-term corticosteroid therapy with favorable clinical and radiologic outcomes. During the follow-up, the patient reported right hypochondrial pain. The laboratory workup revealed a prothrombin level of 76%, seven-times-normal anicteric biological cholestasis, and a twice-normal cytolysis. The hepatic angioscanner revealed an absence of opacification of the left and median supra-hepatic veins with perfusion abnormalities in the left liver, all consistent with BCS (Fig. 2). Fibroscopy revealed grade I esophageal varices.

As part of the etiologic evaluation of the BCS, a complete investigation including hereditary and acquired prothrombotic conditions was performed with a negative result.

3. DISCUSSION

Liver damage during sarcoidosis is common but rarely symptomatic. In the minority of symptomatic cases, cholestasis is most often discovered during follow-up of known patients with systemic sarcoidosis, which is the case of our patient [8-10]. Liver biology and imaging are recommended during the initial evaluation of sarcoidosis in order to early detect liver damage [11]. Liver biopsy is indicated in cases of moderate or severe disturbances of liver tests [11].
More serious complications such as severe anicteric cholestasis, portal hypertension, BCS or cirrhosis are less common [7,13].

In present case report, an exceptional case of a multisystemic sarcoidosis complicated by a portal cavernoma has been presented. The literature search revealed only 11 cases of BCS related to hepatic sarcoidosis including two pediatric cases [13-23]. The main mechanism of BCS complicating sarcoidosis is not clearly elucidated. Granulomatous lesions are thought to cause external compression of the hepatic veins. They can also directly involve the vascular wall, resulting in lumen narrowing and leading to venous stasis and thrombotic occlusion [12,14,16]. We believe that the development of BCS in our patient may be due to both extrinsic compression and intrinsic granulomatous infiltration of the hepatic veins.

The treatment of hepatic involvement during sarcoidosis is not well codified. Corticosteroid therapy at a dose of 40-60 mg/kg/day is indicated for moderate to severe hepatic impairment, but cannot prevent progression to cirrhosis and portal hypertension [24]. Treatment of BCS associated with sarcoidosis is based on cause management, venous thrombosis prevention and hepatic venous drainage restoration. This may require thrombolytic treatment, angioplasty, transjugular intrahepatic porto-systemic shunt, surgical shunt, or liver transplantation [25-27].

4. CONCLUSION

Although BCS is an exceptional complication of hepatic sarcoidosis, physicians should always consider it. A Doppler ultrasound should be performed in front of any evocating sign, in order to establish an early diagnosis. However, the progression to portal hypertension and hepatocellular failure is unpredictable.

CONSENT

As per international standard or university standard, patient’s consent has been collected and preserved by the authors.

ETHICAL APPROVAL

It is not applicable.
COMPETING INTERESTS
Authors have declared that no competing interests exist.

REFERENCES
24. Bakker GJ, Haan YCL, Maillet de Buy Wenniger LJ, Beuers U. Sarcoidosis of the